A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the safety and efficacy of this antibody in participants with rheumatoid arthritis.

Part A of the study is an initial dose escalation phase

Part B of the study is a randomized allocation of the entire dosing group to parallel treatment assignments

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• diagnosis of rheumatoid arthritis

• regular use of methotrexate

• active rheumatoid arthritis

Exclusion Criteria:

• Juvenile Rheumatoid Arthritis

• evidence of tuberculosis

• women who are pregnant or become pregnant during study, or are breast-feeding